~~<i id='F52B2CE292'><strike id='F52B2CE292'><tt id='F52B2CE292'><pre id='F52B2CE292'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：entertainment 2025-08-05 22:34:10 Page View：9141

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT series 'Denied by AI' wins major journalism prizes
Next article： The high cost of giving birth even with insurance

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

1:29FILE-ThiscombooffileimagesshowsFacebookCEOMarkZuckerberg,left,andTeslaandSpaceXCEOElonMusk.ElonM

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Cherokee Nation medical school graduates its first class

ChoctawNationofOklahomaChiefGaryBatton(left)speakswithCaitlinCosby(right),aChoctawNationcitizenandne